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Breast cancer is a heterogeneous disease
characterized by a widely variable morphological
appearance, many risk factors and distinct gene expression
profiles [1, 2]. Common genetic alterations (e.g.
polymorphisms), with possible effects on protein function
and/or expression, within genes involved in essential
cellular pathways, such as carcinogen metabolism, DNA
repair, cell cycle control and cell proliferation, can
predispose individuals to various tumours, including breast
cancer [3-7].
Remarkable efforts have been made to define the
genetic susceptibility factors that help to identify women
expected to develop breast cancer. The recent study
performed by Lubinski et al. [8] is a promising one.
This work takes into account several critical points in
these types of association studies. First of all, they used
a large sample of randomized cancer cases and
unaffected matched controls, which produce adequate
statistical power (superior to 80%, calculated in
http://www.openepi.com/Menu/OpenEpiMenu.htm).
A recent report suggests that studies regarding the
association between genetic variants and cancer must
take into account not only the statistical significance
(P-value) but also the false positive report probability
(FPRP) [9]. We think that the use of the FPRP criterion
will be helpful to validate their results.
Another important improvement made in this work
was the stratification of the cases in more homogeneous
groups, considering relevant factors in the multifactorial
aetiology of this disease, including not only the
morphology of the lesion (histological type and grade),
but also the hormonal receptor status. This consideration
is of extreme importance, since nowadays breast cancer
morphological classification is being remodelled using
expression profile analysis through cDNA microarrays
that can be translated to routine practice using
immunohistochemistry for some markers [10]. This
approach has redefined breast cancer taxonomy and
identified distinct subtypes of carcinomas: luminal 
(A and B), normal breast-like, HER2 overexpressing and
basal-like [2, 10]. These molecular subtypes not only
reflect the heterogeneity of breast carcinomas and the
possible different cell lineage pathways in breast
carcinogenesis, but also demonstrate the difference in
clinical outcome. It is quite interesting to see in the results
of Lubinski et al. [8] that some markers, such as
CDKN24, are associated with ductal carcinomas that
were high grade and ER positive, which probably
corresponds to the subtype luminal B defined by the
molecular classification. It will be very interesting in future
studies to look for associations of the different markers
with different molecular subtypes of breast carcinomas
that could be quite relevant for strategies of prevention
and treatment. 
Since a large proportion of genetic polymorphisms
do not confer a specific phenotypic alteration, selection
of the criterion used to choose the genetic susceptibility
markers to analyse is critical. A good approach is to
include haplotype-tagging polymorphisms investigating
genetic variation across the gene or locus, using the
phenomenon of linkage disequilibrium. In this way, we
think that the authors would improve their results if they
performed the genetic polymorphism screening on a vast
number of genes and/or loci. Nowadays, technical and
bioinformatics resources are available (for example: SNP
chips), allowing the assay of several hundred polymor-
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phisms simultaneously, improving the chance of finding
a haplotype as a susceptibility marker for the disease [11].
The major limitation at this moment for the widespread
use of these approaches is that they are very expensive.
In the design of case-control association studies,
another determinant feature is the homogeneity between
the two groups, minimizing the bias introduced. In our
opinion, the authors performed case-control matching
well, considering important breast cancer risk factors,
such as age, gender, ethnicity, geographic location and
cancer family history [1]. It is also well known that
prevalence of the genetic variants differs across
racial/ethnic and geographic groups [3, 12]. This
phenomenon was considered by Lubinski et al. [8], in
their study performed in individuals from 
a specific region of Poland. In this way, their results may
or may not be reproducible in other populations, which
makes it important to carry out similar studies on them.
To conclude, we believe that the use of moderate
cancer genetic risk markers, considering the polymorphic
haplotypes in routine practice, will be valuable to
delineate primary preventive strategies regarding lifestyle
(e.g. diet, exercise) and chemoprevention. In turn,
secondary prevention will address public health screening
to identify at-risk individuals, allowing physicians to give
counselling based on the assessment of genetic risk.
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